非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议

2021-03-25 中国肿瘤科相关专家小组(统称) 中国肺癌杂志.2021.24(3):141-160.

肺癌围手术期治疗(术前新辅助治疗及术后辅助治疗)作为手术的重要辅助手段,已成为非小细胞肺癌(non-small cell lung cancer, NSCLC)全程管理中越来越重要的环节。近年来,小规

中文标题:

非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议

发布日期:

2021-03-25

简要介绍:

肺癌围手术期治疗(术前新辅助治疗及术后辅助治疗)作为手术的重要辅助手段,已成为非小细胞肺癌(non-small cell lung cancer, NSCLC)全程管理中越来越重要的环节。近年来,小规模临床研究发现免疫新辅助治疗主要病理缓解率明显提升,甚至达到完全病理缓解,有望成为NSCLC治疗的重要组成部分。然而,免疫新辅助治疗带来疗效和生存获益,同时,其相关严重不良反应(延误手术、丧失手术机会、死亡等)备受关注。本诊疗建议目的是针对免疫检查点抑制剂相关不良反应(immune-related adverse event, irAE)形成适合国内医疗现状的诊疗方案。方法 本文由胸外科专家、肿瘤学专家、胸内科专家以及irAE相关科室专家(消化内科、呼吸内科、心血管内科、感染内科、血液内科、内分泌科、风湿免疫科、神经内科、皮肤科和急诊科)共同完成本诊疗意见的制定工作。专家充分参考irAE指南、胸外科公开发表的大型临床研究数据以及国内医生的临床实战经验和公开发表个案,多学科反复讨论,形成针对围手术期免疫治疗相关不良反应的诊疗建议。结果 本诊疗意见涵盖irAE相关的预防、评估、检查、治疗和监测全过程,以便全面、有效的指导临床工作。结论 围手术期irAE管理是肺癌免疫围手术期治疗的重要组成部分,随着免疫围手术期治疗的不断发展,未来需要更多的研究,以优化围手术irAE的诊疗。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议_倪军.pdf)] GetToolGuiderByIdResponse(projectId=1, id=bbcd41c0020896e8, title=非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议, enTitle=, guiderFrom=中国肺癌杂志.2021.24(3):141-160., authorId=0, author=, summary=肺癌围手术期治疗(术前新辅助治疗及术后辅助治疗)作为手术的重要辅助手段,已成为非小细胞肺癌(non-small cell lung cancer, NSCLC)全程管理中越来越重要的环节。近年来,小规, cover=https://img.medsci.cn/2021426/1619449097934_2020535.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Thu Mar 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>肺癌围手术期治疗(术前新辅助治疗及术后辅助治疗)作为手术的重要辅助手段,已成为非小细胞肺癌(non-small cell lung cancer, NSCLC)全程管理中越来越重要的环节。近年来,小规模临床研究发现免疫新辅助治疗主要病理缓解率明显提升,甚至达到完全病理缓解,有望成为NSCLC治疗的重要组成部分。然而,免疫新辅助治疗带来疗效和生存获益,同时,其相关严重不良反应(延误手术、丧失手术机会、死亡等)备受关注。本诊疗建议目的是针对免疫检查点抑制剂相关不良反应(immune-related adverse event, irAE)形成适合国内医疗现状的诊疗方案。方法 本文由胸外科专家、肿瘤学专家、胸内科专家以及irAE相关科室专家(消化内科、呼吸内科、心血管内科、感染内科、血液内科、内分泌科、风湿免疫科、神经内科、皮肤科和急诊科)共同完成本诊疗意见的制定工作。专家充分参考irAE指南、胸外科公开发表的大型临床研究数据以及国内医生的临床实战经验和公开发表个案,多学科反复讨论,形成针对围手术期免疫治疗相关不良反应的诊疗建议。结果 本诊疗意见涵盖irAE相关的预防、评估、检查、治疗和监测全过程,以便全面、有效的指导临床工作。结论 围手术期irAE管理是肺癌免疫围手术期治疗的重要组成部分,随着免疫围手术期治疗的不断发展,未来需要更多的研究,以优化围手术irAE的诊疗。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9617, appHits=121, showAppHits=0, pcHits=437, showPcHits=9496, likes=1, shares=10, comments=7, approvalStatus=1, publishedTime=Mon Apr 26 23:27:36 CST 2021, publishedTimeString=2021-03-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 26 22:58:26 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Wed Jan 03 13:11:51 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议_倪军.pdf)])
非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议_倪军.pdf
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072189, encodeId=880810e2189a2, content=、…学了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbbc5723650, createdName=ms9000000080461052, createdTime=Sat Nov 20 12:38:30 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070173, encodeId=404a10e0173a7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb22269338, createdName=1219f53dm03暂无昵称, createdTime=Sun Nov 14 15:48:19 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998505, encodeId=94c89985050b, content=怎么下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/16/798856c797705711ecf53e23308e6ebf.jpg, createdBy=6e612127673, createdName=曩盲, createdTime=Sun Jul 11 15:56:35 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971581, encodeId=39189e1581f0, content=如何下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c885512638, createdName=GiannaWEN, createdTime=Mon Jun 07 18:01:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961121, encodeId=89c796112167, content=有实践指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Apr 28 08:50:03 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-11-20 ms9000000080461052

    、…学了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072189, encodeId=880810e2189a2, content=、…学了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbbc5723650, createdName=ms9000000080461052, createdTime=Sat Nov 20 12:38:30 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070173, encodeId=404a10e0173a7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb22269338, createdName=1219f53dm03暂无昵称, createdTime=Sun Nov 14 15:48:19 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998505, encodeId=94c89985050b, content=怎么下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/16/798856c797705711ecf53e23308e6ebf.jpg, createdBy=6e612127673, createdName=曩盲, createdTime=Sun Jul 11 15:56:35 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971581, encodeId=39189e1581f0, content=如何下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c885512638, createdName=GiannaWEN, createdTime=Mon Jun 07 18:01:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961121, encodeId=89c796112167, content=有实践指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Apr 28 08:50:03 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-11-14 1219f53dm03暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1072189, encodeId=880810e2189a2, content=、…学了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbbc5723650, createdName=ms9000000080461052, createdTime=Sat Nov 20 12:38:30 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070173, encodeId=404a10e0173a7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb22269338, createdName=1219f53dm03暂无昵称, createdTime=Sun Nov 14 15:48:19 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998505, encodeId=94c89985050b, content=怎么下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/16/798856c797705711ecf53e23308e6ebf.jpg, createdBy=6e612127673, createdName=曩盲, createdTime=Sun Jul 11 15:56:35 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971581, encodeId=39189e1581f0, content=如何下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c885512638, createdName=GiannaWEN, createdTime=Mon Jun 07 18:01:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961121, encodeId=89c796112167, content=有实践指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Apr 28 08:50:03 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-07-11 曩盲

    怎么下载

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1072189, encodeId=880810e2189a2, content=、…学了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbbc5723650, createdName=ms9000000080461052, createdTime=Sat Nov 20 12:38:30 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070173, encodeId=404a10e0173a7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb22269338, createdName=1219f53dm03暂无昵称, createdTime=Sun Nov 14 15:48:19 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998505, encodeId=94c89985050b, content=怎么下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/16/798856c797705711ecf53e23308e6ebf.jpg, createdBy=6e612127673, createdName=曩盲, createdTime=Sun Jul 11 15:56:35 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971581, encodeId=39189e1581f0, content=如何下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c885512638, createdName=GiannaWEN, createdTime=Mon Jun 07 18:01:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961121, encodeId=89c796112167, content=有实践指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Apr 28 08:50:03 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-06-07 GiannaWEN

    如何下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1072189, encodeId=880810e2189a2, content=、…学了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbbc5723650, createdName=ms9000000080461052, createdTime=Sat Nov 20 12:38:30 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070173, encodeId=404a10e0173a7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb22269338, createdName=1219f53dm03暂无昵称, createdTime=Sun Nov 14 15:48:19 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998505, encodeId=94c89985050b, content=怎么下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/16/798856c797705711ecf53e23308e6ebf.jpg, createdBy=6e612127673, createdName=曩盲, createdTime=Sun Jul 11 15:56:35 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971581, encodeId=39189e1581f0, content=如何下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c885512638, createdName=GiannaWEN, createdTime=Mon Jun 07 18:01:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961121, encodeId=89c796112167, content=有实践指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Apr 28 08:50:03 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-04-28 carolinewy

    有实践指导意义

    0

拓展阅读

ASCO指南:IV期非小细胞肺癌的维持治疗(2009)

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2010ESMO临床实践指南:早期和局部晚期(非转移性)非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南:转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01